Exciting Partnership Announcement: MGI and Lexogen Collaborate to Validate QuantSeq and CORALL Libraries on DNBSEQ™ Technology

We are thrilled to announce that QuantSeq and CORALL, Lexogen's flagship library preparation kits, have been validated for usage on MGI sequencers! With the introduction of the MGIEasy Universal Library Conversion Kit, preparing your RNA library for 3’ mRNA-Seq (QuantSeq) or whole-transcriptome RNA-Seq (CORALL) has never been easier. Coupled with MGI’s innovative DNBSEQ^TM chemistry, sequencing your libraries promises unparalleled efficiency and accuracy.

Integration of Lexogen's patented 12 nt Unique Dual Indices (UDI) into each sample allows seamless pooling of different Lexogen libraries. Lexogen’s 12 nt UDI offer ultimate precision for library allocation during data analysis, providing researchers with confidence in their results.

Moreover, the quality scores delivered by this collaboration consistently exceed Q30, even at 150 bp length. This ensures optimal gene identification, gene expression analysis, and isoform detection (CORALL only), empowering researchers with robust data for their experiments.

“We are incredibly excited about the opportunities this collaboration brings for advancing RNA sequencing technology. The association of Lexogen's expertise in library preparation with MGI's cutting-edge sequencing platforms opens new avenues for researchers to explore and discover." – say Filippo Passardi, Product Manager at Lexogen.

” It was a pleasure to validate this Lexogen solution with our sequencing technology and work together with a great team. We know our platforms deliver outstanding sequencing results and partners like Lexogen fill our platforms with applications tailored to our customers needs.” – say Laura Pellegrino, FAS and Project Manager at MGI.

Are you planning a new RNA-Seq experiment with MGI sequencers? Don't hesitate any longer! Contact us today to learn more about how our collaboration can elevate your research.

For inquiries, please reach out to: [email protected] (Lexogen) or [email protected] ( MGI).

About Lexogen

Established in 2007, Lexogen is a leading company in transcriptomics, next-generation sequencing, and RNA analysis. The mission of the Lexogen team is to empower their customers with innovative top quality RNA analysis solutions and support. Lexogen is the inventor of 3’ RNA sequencing, a unique technology proven for its efficiency, robustness, and sensitivity, especially unmatched for differential gene expression analysis. Lexogen’s proprietary portfolio includes innovative kits for true single-cell as well as bulk RNA sequencing, RNA extraction, ribosomal RNA depletion, spike-in RNA variant controls, and kinetic RNA labeling. Lexogen also provides first-class, fully integrated NGS services from experimental design to analytical reporting. Lexogen is a privately held company, headquartered in Vienna, Austria with a subsidiary in New Hampshire, USA.

To learn more, visit lexogen and follow @lexogen.

About MGI

MGI is a leading producer of clinical high-throughput gene sequencers and automation platforms with a vision to lead life science through Intelligent innovation. MGI takes pride in its ability to develop and manufacture a full spectrum of instruments, ranging from low to extra-high throughput genetic sequencers, accelerating scientific breakthroughs for our scientists.